New Covenant Trust Company, N.A. Denali Therapeutics Inc. Transaction History
New Covenant Trust Company, N.A.
- $99.4 Million
- Q1 2024
A detailed history of New Covenant Trust Company, N.A. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, New Covenant Trust Company, N.A. holds 784 shares of DNLI stock, worth $18,894. This represents 0.02% of its overall portfolio holdings.
Number of Shares
784Holding current value
$18,894% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
220Shares Held
115MCall Options Held
142KPut Options Held
90.3K-
Baillie Gifford & CO13.8MShares$332 Million0.25% of portfolio
-
Black Rock Inc. New York, NY12.2MShares$294 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$264 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.27MShares$199 Million0.03% of portfolio
-
State Street Corp Boston, MA6.32MShares$152 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.23B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...